Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
PARIS & Vivet Therapeutics ("Vivet"), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
More News: Biotechnology | Gene Therapy | Genetics | Liver | Pfizer | Pharmaceuticals | Urology & Nephrology